Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-22T10:50:28.592Z Has data issue: false hasContentIssue false
  • English
  • Français

Carriage of Staphylococcus aureus Among Injection Drug Users: Lower Prevalence in an Injection Heroin Maintenance Program Than in an Oral Methadone Program

Published online by Cambridge University Press:  02 January 2015

Stefano Bassetti ,
Lea Wolfisberg ,
Barbara Jaussi ,
Reno Frei ,
Marcus F. Kuntze ,
Manuel Battegay  and
Andreas F. Widmer
Stefano Bassetti*
Affiliation:
Division of Infections Diseases, University Hospital Basel, Basel, Switzerland
Lea Wolfisberg
Affiliation:
Division of Infections Diseases, University Hospital Basel, Basel, Switzerland
Barbara Jaussi
Affiliation:
Division of Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
Reno Frei
Affiliation:
Bacteriology Laboratory, University Hospital Basel, Basel, Switzerland
Marcus F. Kuntze
Affiliation:
Psychiatrie University Clinic Basel, Basel, Switzerland
Manuel Battegay
Affiliation:
Division of Infections Diseases, University Hospital Basel, Basel, Switzerland
Andreas F. Widmer
Affiliation:
Division of Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
*
Division of Infections Diseases, University Hospital Basel, CH - 4031 Basel, Switzerland
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To compare the prevalence of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) carriage among injection drug users (IDUs) treated in an injection heroin maintenance program with that among IDUs treated in an oral methadone program, and to determine predictors of S. aureus carriage.

Design:

Survey.

Setting:

Two opiate maintenance programs at a psychiatrie university clinic.

Participants:

A volunteer sample consisting of 94 (74%) of 127 IDUs treated in an injection opiate maintenance program with at least twice daily injections of heroin, and 70 (56%) of 125 IDUs treated in an oral methadone program.

Results:

Addicts treated in the intravenous heroin substitution program had a significantly lower overall rate of S. aureus carriage (37 of 94 [39.4%] vs 42 of 70 [60%]; P = .009) and a significantly lower rate of nasal carriage (21 of 94 [22.3%] vs 30 of 70 [42.9%]; P = .005) than did addicts treated in the oral methadone program. Being treated in the oral methadone program was the only independent predictor of S. aureus carriage (odds ratio, 2.27; 95% confidence interval, 1.19-4.31; P=.012). All S. aureus isolates were susceptible to oxacillin.

Conclusions:

The regular use of needles under aseptic conditions did not increase the rate of S. aureus carriage among IDUs. Further studies are necessary to investigate whether the lower rate of S. aureus carriage among IDUs treated with intravenous heroin leads to a lower incidence of S. aureus infections in these patients.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 25 , Issue 2 , February 2004 , pp. 133 - 137
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Cherubin, CE, Sapira, JD. The medical complications of drug addiction and the medical assessment of intravenous drug users: 25 years later. Ann Intern Med 1993;119:1017–1028.Google Scholar
2.Palepu, A, Tyndall, MW, Leon, H, et al.Hospital utilization and costs in a cohort of injection drug users. CMAJ 2001;165:415–420.Google Scholar
3.Bassetti, S, Hoffmann, M, Bucher, HC, Fluckiger, U, Battegay, M. Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program. Clin Infect Dis 2002;34:711–713.Google Scholar
4.Saravolatz, LD, Markowitz, N, Arking, L, Pohlod, D, Fisher, E. Methicillin-resistant Staphylococcus aureus: epidemiologic observations during a community-acquired outbreak. Ann Intern Med 1982;96:11–16.CrossRefGoogle ScholarPubMed
5.Fleisch, F, Zbinden, R, Vanoli, C, Ruef, C. Epidemie spread of a single clone of methicillin-resistant Staphylococcus aureus among injection drug users in Zurich, Switzerland. Clin Infect Dis 2001;32:581–586.Google Scholar
6.Kluytmans, J, van Belkum, A, Verbrugh, H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 1997;10:505–520.Google Scholar
7.von Eiff, C, Becker, K, Machka, K, Stammer, H, Peters, G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001;344:11–16.Google Scholar
8.Peacock, S, de Silva, I, Lowy, FD. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol 2001;9:605–610.Google Scholar
9.Tuazon, CU, Sheagren, JN. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974;129:725–727.Google Scholar
10.Kirmani, N, Tuazon, CU, Alling, D. Carriage rate of Staphylococcus aureus among patients receiving allergy injections. Annals ofAllergy 1980;45:235–237.Google Scholar
11.Rehm, J, Gschwend, P, Steffen, T, Gutzwiller, F, Dobler-Mikola, A, Uchtenhagen, A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001;358:1417–1420.Google Scholar
12.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001. Document M100-S11.Google Scholar
13.Bassetti, S, Dunagan, DP, D'Agostino, RB, Sherertz, RJ. Nasal carriage of Staphylococcus aureus among patients receiving allergen-injection immunotherapy: associated factors and quantitative nasal cultures. Infect Control Hosp Epidemiol 2001;22:741–745.Google Scholar
14.Holbrook, KA, Klein, RS, Hartel, D, et al.Staphylococcus aureus nasal colonization in HrV-seropositive and HIV-seronegative drug users. J Acquirlmmune Defic Syndr 1997;16:301–306.Google Scholar
15.Shuter, J, Hatcher, VB, Lowy, FD. Staphylococcus aureus binding to human nasal mucin. Infect Immun 1996;64:310–318.CrossRefGoogle ScholarPubMed
16.Bibel, DJ, Aly, R, Shinefield, HR, Maibach, HI, Strauss, WG. Importance of the keratinized epithelial cell in bacterial adherence. J Invest Dermatol 1982;79:250–253.CrossRefGoogle ScholarPubMed
17.Lowy, FD, Miller, M. New methods to investigate infectious disease transmission and pathogenesis: Staphylococcus aureus disease in drug users. Lancet Infect Dis 2002;2:605–612.Google Scholar
18.Perneger, TV, Giner, F, del Rio, M, Mino, A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998;317:13–18.Google Scholar
19.Steffen, T, Blattler, R, Gutzwiller, F, Zwahlen, M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001;11:425–430.Google Scholar
20.Naef, MR, Bucher, HC, Erb, P, Gyr, N, Bassetti, S, Battegay, M. Reduced infections with HIV and hepatitis A during a Swiss intravenous opiate maintenance program. J Acquir Immune Defic Syndr 1999;21:349–351.Google Scholar
21.Conrad, C, Steffen, T, Gutzwiller, F. Die Entwicklung von Hauterkrankungen bei intravenos Drogenabhangigen in der hero-ingestutzten Behandlung. Schiveiz Rundsch Med Prax 2000;89:1899–1906.Google Scholar
22.Blanc, DS, Pittet, D, Ruef, C, et al.Epidemiology of methicillin-resistant Staphylococcus aureus: results of a nation-wide survey in Switzerland. Swiss Med Wkly 2002;132:223–229.Google Scholar